Wealth Enhancement Advisory Services
HRTX icon

Wealth Enhancement Advisory Services’s Heron Therapeutics HRTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.4K Sell
29,067
-3,330
-10% -$1.26K ﹤0.01% 4196
2026
Q2 		$13.4K Buy
32,397
+15,793
+95% +$12.7K ﹤0.01% 4081
2026
Q1 		$13.3K Buy
+16,604
New +$19.2K ﹤0.01% 3537
2025
Q4 		– Sell
-25,577
Closed -$33.8K – 3715
2025
Q3 		$33.8K Sell
25,577
-11,551
-31% -$18.3K ﹤0.01% 3463
2025
Q2 		$81.7K Buy
37,128
+1,512
+4% +$3.09K ﹤0.01% 3169
2025
Q1 		$78.4K Buy
35,616
+482
+1% +$935 ﹤0.01% 2806
2024
Q4 		$53.8K Sell
35,134
-10,139
-22% -$16.4K ﹤0.01% 2860
2024
Q3 		$90.1K Buy
45,273
+7,927
+21% +$18.9K ﹤0.01% 2575
2024
Q2 		$131K Buy
37,346
+1,366
+4% +$4.2K ﹤0.01% 2368
2024
Q1 		$100K Buy
35,980
+9
+0% +$23 ﹤0.01% 2295
2023
Q4 		$61.2K Sell
35,971
-1,640
-4% -$1.81K ﹤0.01% 2205
2023
Q3 		$38.7K Buy
+37,611
New +$53.5K ﹤0.01% 2171

Other funds holding HRTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Tejara Capital
Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Wealth Enhancement Advisory Services's HRTX Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its Heron Therapeutics (HRTX) stake by 10% in Q3 2026, selling an estimated $1.26K and leaving 29,067 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4196.

Wealth Enhancement Advisory Services first reported a position in HRTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $131K in Q2 2024. 121 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

  • Wealth Enhancement Advisory Services held 29,067 shares of Heron Therapeutics worth $10.4K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 3,330 Heron Therapeutics shares in Q3 2026, an estimated $1.26K.
  • Heron Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4196 holding.
  • Wealth Enhancement Advisory Services first reported a position in Heron Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Wealth Enhancement Advisory Services's Heron Therapeutics position peaked at $131K in Q2 2024.
  • 121 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.